Breast cancer is a leading cause of cancer-related mortality in women, and the expression profiles of specific tumor biomarkers are strongly associated with unfavorable prognosis. Herein, we engineered a dual-signal electrochemical aptasensor for the simultaneous quantification of clinically critical cancer biomarkers EGFR and HER2, enabling precise tumor phenotype characterization. The platform integrates two innovative probes: Fe3O4@UiO-66/Au functionalized with methylene blue/ferrocene-labeled aptamers (Probe1) for magnetic capture and signal amplification; aptamer-functionalized DNA nanotetrahedron (Probe2)-modified screen-printed carbon electrode for enhanced target recognition. The “Probe1-target-Probe2” sandwich architecture generates distinct electrochemical signals, achieving ultrahigh sensitivity (limit of detection: EGFR: 0.035 pg/mL; HER2: 0.043 pg/mL) with robust serum recovery. The electrochemical biosensor directly quantified EGFR/HER2 expression on breast cancer cells with results perfectly correlated with the highly expensive and experience-dependent flow cytometry for subtype stratification (MCF-7 cell: low EGFR/high HER2; MDA-MB-231 cell: high EGFR/low HER2; SK-BR-3 cell: moderate EGFR/HER2). Remarkably, the aptasensor achieved an ultra-low detection limit of 3 cells/mL for MCF-7, MDA-MB-231, and SK-BR-3 cells. This platform offers transformative advantages over conventional methods, including cost-effectiveness, rapid analysis, eliminating fluorescent tags, and a wide linear dynamic range. This work establishes a highly practical and sensitive platform for tumor marker profiling and electrochemical characterization of breast cancer subtypes.
扫码关注我们
求助内容:
应助结果提醒方式:
